Clinical trial
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
NCT00419146 · University Hospital, Aker, Other · Completed
Key facts
| NCT number | NCT00419146 |
|---|---|
| Title | Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants |
| Official title | A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders |
| Lead sponsor | University Hospital, Aker, Other |
| Collaborators | Diakonhjemmet Hospital Stanley Medical Research Institute Laxdale Ltd Scandinavian Society for Psychopharmacology Shipowner Emil Stray's legacy Johanne and Einar Eilertsen's research fund AstraZeneca… |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychotic Disorders |
| Intervention type | Drug, Other |
| Interventions | Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C, Etyl EPA (placebo), Vitamins E+C (placebo) |
| Enrollment | 99 |
| Start date | Sep 1, 2001 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Jan 8, 2007 |
| Last update posted | Jan 4, 2011 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: